Pharsight

Neupro generic

Neupro is an anti-Parkinson's disease and Restless Legs Syndrome drug owned by Ucb Inc. Its major active component is rotigotine. The drug was authorised for market use on 9th May 2007, and it is available in the form of a film, extended release; transdermal dosage. Neupro holds a total of 6 patents, with one already expired.

When will Neupro generic be available?

With one of Neupro's patents already expired and the latest one set to expire on 1st March 2032, the generic versions of this drug might be available post this date. However, the exact availability of the Neupro generic would depend on factors such as Para IV filings.

Neupro uses

Neupro is primarily used for the treatment of signs and symptoms of Parkinson's disease and Restless Legs Syndrome. It works by administering rotigotine through a transdermal delivery system directly applied to the patient's skin. This method enhances the effectiveness of the drug for the patient suffering from these conditions.

Neupro patent expiration

Neupro is protected by 6 patents with the last one set to expire on 1st March 2032. One of these patents has already expired. The remaining patents pertain to various aspects of the drug, from its transdermal delivery system to the use of Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of Rotigotine. Here are more details on the patents protecting Neupro generic from release:

EPO Oppostions filed on Neupro

Neupro dosage

Want to ask something?